TY - JOUR
T1 - L-arginine partially reverses established adrenocorticotrophin-induced hypertension and nitric oxide deficiency in the rat
AU - Wen, C.
AU - Li, M.
AU - Fraser, T.
AU - Wang, J.
AU - Turner, S. W.
AU - Whitworth, J. A.
PY - 2000
Y1 - 2000
N2 - Background: L-arginine treatment prevents adrenocorticotrophin (ACTH) induced hypertension in the rat. This study examined whether L-arginine treatment could reverse established ACTH hypertension and its effects on markers of decreased NO activity. Methods: Sixty-four male Sprague-Dawley rats were randomly divided into 6 groups given 12 days of treatment: (1) sham (0.9% NaCl, 0.5 ml/kg, subcutaneously, sc, n = 16); (2) ACTH (0.5 mg/kg/day, sc, n = 16); (3) sham + L-arginine (0.6% in food, from treatment day 8 onwards, n = 10); (4) ACTH + L-arginine (n = 10); (5) sham + D-arginine (0.6% in food, from T 8 onwards) (n = 6); and (6) ACTH + D-arginine (n = 6). Systolic blood pressure, water intake, urine volume, and body weight were measured every second day. At the end of the experiments, plasma and urinary nitrate/nitrite (NOx), plasma amino acid concentrations (in groups 1-4), and urinary cyclic guanosine monophosphate (cGMP) concentrations were measured. Results: Sham, sham + L-arginine, and sham + D-arginine treatments did not affect blood pressure. ACTH increased systolic blood pressure (from 121 ± 1 to 147 ± 2 mmHg, p < 0.001, pooled control vs treatment day 12, mean ± sem), and this was partially reversed by L-arginine (group 4: From 141 ± 2 on day 8 to 133 ± 1 mmHg on day 12, n = 10, p < 0.001). In contrast, D-arginine did not affect blood pressure in ACTH-treated rats (group 6). ACTH increased water intake and urine volume and decreased body weight, and L-arginine administration did not alter these parameters. ACTH decreased plasma citrulline (group 1 vs 2:115 ± 7 vs 67 ± 6 μ M/L, n = 16, p < 0.001) and NOx concentrations (group 1 vs 2: 8.3 ± 0.8 vs 4.5 ± 0.6 μ M/L, n= 10, p < 0.001) and these decreases were reversed by L-arginine treatment (group 4: Citrulline 98 ± 9 μ M/L, NOx 9.1 ± 1.6 μ M/L, group 2 vs 4, both p < 0.05). ACTH produced marked increases in urinary cGMP excretion (group 1 vs 2:0.5 ± 0.1 vs 1.9 ± 0.4 nmol/24 h, p < 0.01). Conclusion: Supplementation with L-arginine partly reversed established ACTH-induced hypertension and restored plasma NOx and citrulline concentrations to levels seen in sham-treated rats. These data are consistent with previous studies suggesting that functional NO deficiency has a role in ACTH-induced hypertension in rats.
AB - Background: L-arginine treatment prevents adrenocorticotrophin (ACTH) induced hypertension in the rat. This study examined whether L-arginine treatment could reverse established ACTH hypertension and its effects on markers of decreased NO activity. Methods: Sixty-four male Sprague-Dawley rats were randomly divided into 6 groups given 12 days of treatment: (1) sham (0.9% NaCl, 0.5 ml/kg, subcutaneously, sc, n = 16); (2) ACTH (0.5 mg/kg/day, sc, n = 16); (3) sham + L-arginine (0.6% in food, from treatment day 8 onwards, n = 10); (4) ACTH + L-arginine (n = 10); (5) sham + D-arginine (0.6% in food, from T 8 onwards) (n = 6); and (6) ACTH + D-arginine (n = 6). Systolic blood pressure, water intake, urine volume, and body weight were measured every second day. At the end of the experiments, plasma and urinary nitrate/nitrite (NOx), plasma amino acid concentrations (in groups 1-4), and urinary cyclic guanosine monophosphate (cGMP) concentrations were measured. Results: Sham, sham + L-arginine, and sham + D-arginine treatments did not affect blood pressure. ACTH increased systolic blood pressure (from 121 ± 1 to 147 ± 2 mmHg, p < 0.001, pooled control vs treatment day 12, mean ± sem), and this was partially reversed by L-arginine (group 4: From 141 ± 2 on day 8 to 133 ± 1 mmHg on day 12, n = 10, p < 0.001). In contrast, D-arginine did not affect blood pressure in ACTH-treated rats (group 6). ACTH increased water intake and urine volume and decreased body weight, and L-arginine administration did not alter these parameters. ACTH decreased plasma citrulline (group 1 vs 2:115 ± 7 vs 67 ± 6 μ M/L, n = 16, p < 0.001) and NOx concentrations (group 1 vs 2: 8.3 ± 0.8 vs 4.5 ± 0.6 μ M/L, n= 10, p < 0.001) and these decreases were reversed by L-arginine treatment (group 4: Citrulline 98 ± 9 μ M/L, NOx 9.1 ± 1.6 μ M/L, group 2 vs 4, both p < 0.05). ACTH produced marked increases in urinary cGMP excretion (group 1 vs 2:0.5 ± 0.1 vs 1.9 ± 0.4 nmol/24 h, p < 0.01). Conclusion: Supplementation with L-arginine partly reversed established ACTH-induced hypertension and restored plasma NOx and citrulline concentrations to levels seen in sham-treated rats. These data are consistent with previous studies suggesting that functional NO deficiency has a role in ACTH-induced hypertension in rats.
KW - Adrenocorticotropic hormone (ACTH)
KW - Amino acids
KW - Arginine
KW - Blood pressure
KW - Hypertension
KW - Rats
UR - http://www.scopus.com/inward/record.url?scp=0034544790&partnerID=8YFLogxK
U2 - 10.1080/080370500448704
DO - 10.1080/080370500448704
M3 - Article
SN - 0803-7051
VL - 9
SP - 298
EP - 304
JO - Blood Pressure
JF - Blood Pressure
IS - 5
ER -